Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment

Background: Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Reports indicate that the antibody (Ab) response in MM after 1 dose of SARS-CoV-2 RNA vaccine is attenuated. The impact of treatment on cellular immunity after...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Oekelen, Oliver, Agte, Sarita, Aleman, Adolfo, Upadhyaya, Bhaskar, Gleason, Charles R., Srivastava, Komal, Beach, Katherine F., Tuballes, Kevin, Kappes, Katerina, Mouhieddine, Tarek H., Wang, Bo, Kim-Schulze, Seunghee, Chari, Ajai, Gnjatic, Sacha, Bhardwaj, Nina, Brown, Brian D., Merad, Miriam, Cordon-Cardo, Carlos, Krammer, Florian, Jagannath, Sundar, Simon, Viviana, Wajnberg, Ania, Parekh, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701831/
https://www.ncbi.nlm.nih.gov/pubmed/34499154
http://dx.doi.org/10.1182/blood-2021-152365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701831/
https://www.ncbi.nlm.nih.gov/pubmed/34499154
http://dx.doi.org/10.1182/blood-2021-152365

Ejemplares similares